Leveraging CRISPR 2.0 – 2nd-generation gene-editing tools building on Nobel Prize-winning technology - we address peanut allergies while creating varieties with enhanced health benefits, extended shelf-life, improved climate resilience, and protected yields in a global peanut market worth around $100 billion per year.
Peanuts power a global food and ingredient economy feeding billions worldwide, from smallholder farms and nutrition programs to advanced food and ingredient innovation.
A highly diversified market: Peanut butter (~$8.5 billion), peanut oil (~$8.7 billion), snacks (~$6.5 billion), and industrial ingredients (~$32 billion) together form a robust, fast-evolving value chain.
Three megatrends fuel growth: the plant-protein boom, demand for heart-healthy fats, and the search for affordable, nutrient-dense foods - making peanuts one of the most efficient sources of nutrition per dollar.
Next-generation innovation: peanuts are moving beyond traditional uses into biofuels, advanced ingredients, and novel health applications - turning an ancient crop into a modern platform for food and AgTech innovation.
Peanut allergies affect tens of millions worldwide and represent a growing public health concern.
An unsuitable fat profile undermines product quality, shortens shelf-life and drives large-scale spoilage.
Inefficient harvesting methods due to the plant’s architecture can reduce production by up to 30%, resulting in billions in economic losses.
Aflatoxin contamination affects 20% to 30% of the global peanut butter market.
Emerging heat, drought and diseases will reduce yields by up to 40%.
one super-peanut!
Agrinetica uses advanced CRISPR tools to develop combinations of traits that target the industry’s most pressing challenges, starting with peanut allergies. The objective is a next-generation peanut that improves stability, resilience, and yield potential.
Creating super-peanuts that, under current U.S. law, will not require GMO labelling, as no foreign DNA is introduced, and our traits closely resemble the outcomes of traditional breeding but achieved in a far more targeted and efficient way.
Reduced allergenicity, extended shelf-life, improved climate resilience, and yield protection. We’re addressing life-threatening allergies affecting millions, eliminating crop losses worth billions, improving food quality and safety, and ensuring climate resilience – multiple revolutionary advantages in a single seed that will set the new gold standard for global peanut production.
Applying CRISPR 2.0 to peanuts
Pioneering 2nd-generation CRISPR technology to make next-generation peanut development faster, simpler, and cost-efficient
Enables smoother regulatory approval and broad consumer acceptance without mandatory labelling. Similar labelling is expected globally.
Strong intellectual property protection and early-mover positioning secure a lasting competitive advantage.
Global CRISPR and AgTech experts translating breakthrough science into market impact.
Transforming a $100 billion industry with a scalable, license-based business model and global relevance.
Chairman
CEO & Co-founder
Director
CFO & HR
VP R&D
CTO and Co-founder
Scientific Advisor
Scientific Advisor
Virology Advisor
Breeding & Genetics Advisor
Solving peanut allergy transcends health innovation, it’s a breakthrough that will liberate children and adults from life-threatening reactions, free schools and airlines from peanut bans, and unleash innovation across a food industry long shackled by allergy restrictions.
Creating the next-generation peanut that integrates safety, quality, stability, resilience, and yield protection into a single revolutionary product line.
Through strategic partnerships with growers, processors, and brands, we’re delivering unprecedented value across the entire chain in a market worth nearly $100 billion per year.
